Training towards Personalized Antibiotic Treatment


Antimicrobial resistance (AMR) is an increasing threat to effectively treat serious bacterial infections. To this end, tailoring antibiotic treatments to individual patients is urgently needed to maximize efficacy while minimizing the risk of promoting further resistance. To enable development of innovative personalized antibiotic treatment strategies, quantitative understanding of the interplay between drug, pathogen and host is crucial. The Training towards Innovative Personalized Antibiotic Therapy (TIPAT) network will train inter-disciplinary specialists optimally equipped with a skill set to address this challenge. TIPAT offers a cutting-edge training-by-research programme for 15 Early Stage Researchers (ESRs) who will investigate translation and integration of biological and pharmacological data related to drug-pathogen-host interactions towards personalized therapies. Central to the TIPAT research and training program is the combination of state-of-the art quantitative modelling with approaches in clinical pharmacology, immunology and microbiology, which enables development of innovative methodology to personalized antibiotic therapies. The consortium unites a cross-disciplinary team of leading academic experts and inter-sectoral partners including SMEs, pharmaceutical companies and hospitals. Secondments complementary to ESR research projects will promote inter-professional and cross-disciplinary research and communication. The TIPAT integrated program is enriched with transferable, regulatory and entrepreneurial skills training delivered through themed Summer and Winter schools. The TIPAT network will deliver inter-disciplinary specialists in personalized antibiotic treatment strategies. The TIPAT training will strongly expand career perspectives of ESRs in academia, hospitals, industry or regulatory agencies, and develop scientific innovations to enable optimal therapy for individual patients to address current and future challenges of AMR-infections.

Project details

Unibo Team Leader: Federico Pea

Unibo involved Department/s:
Dipartimento di Scienze Mediche e Chirurgiche

Universiteit Leiden(Netherlands)

Other Participants:
Klinik fur Innere Medizin II - Abteilung Hamatologie und Internistiche Onkologie - Universitatsklinikum Jena (Germany)
UPPSALA UNIVERSITET - Uppsala Genome Center (Sweden)
Veterinaermedizinische Universitaet Wien (Austria)
ALMA MATER STUDIORUM - Università di Bologna (Italy)
Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel (Germany)

Total Eu Contribution: Euro (EUR) 3.969.583,20
Project Duration in months: 46
Start Date: 13/10/2020
End Date: 31/08/2024

Cordis webpage

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 861323 This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 861323